Skip to main content Back to Top
Advertisement

12/2/2022

Oxytocin Injection

Products Affected - Description

    • Pitocin injection, Par Sterile Products, 10 unit/mL, 1 mL vial, 25 count, NDC 42023-0116-25
    • Pitocin injection, Par Sterile Products, 10 unit/mL, 10 mL vial, 25 count, NDC 42023-0116-02
    • Pitocin injection, Par Sterile Products, 10 unit/mL, 50 mL bulk vial, 1 count, NDC 42023-0130-06
    • Oxytocin injection, Fresenius Kabi, 10 unit/mL, 1 mL vial, 25 count, NDC 63323-0012-11
    • Oxytocin injection, Fresenius Kabi, 10 unit/mL, 10 mL vial, 25 count, NDC 63323-0012-10
    • Oxytocin injection, Fresenius Kabi, 10 unit/mL, 30 mL vial, 10 count, NDC 63323-0012-30

Reason for the Shortage

    • Par has seen increased demand of Pitocin.
    • Fresenius Kabi has oxytocin on shortage due to manufacturing delays.

Available Products

    • There are no presentations available

Estimated Resupply Dates

    • Fresenius Kabi has oxytocin 10 units/mL 1 mL, 10 mL, and 30 mL vials on back order and the company estimates a release date of mid-December 2022 for the 1 mL and 10 mL vials and early-December 2022 for the 30 mL vials. Check wholesalers for inventory.
    • Par has regular releases of Pitocin 1 mL, 10 mL, and 50 mL vials but supply is depleted as it becomes available.

Implications for Patient Care

Updated

Updated December 2, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. Created September 13, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.